Terms: = Lymphoma AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Prognosis
18 results:
1. xpo1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53-p21 and p27 pathways.
Chakravarti N; Boles A; Burzinski R; Sindaco P; Isabelle C; McConnell K; Mishra A; Porcu P
Sci Rep; 2024 Apr; 14(1):9305. PubMed ID: 38653804
[TBL] [Abstract] [Full Text] [Related]
2. The synergy of the xpo1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression.
Deng M; Tan J; Fan Z; Pham LV; Zhu F; Fang X; Zhao H; Young K; Xu B
Sci Rep; 2023 Oct; 13(1):18554. PubMed ID: 37899423
[TBL] [Abstract] [Full Text] [Related]
3. The Therapeutic Synergy of Selinexor and Venetoclax in Mantle Cell lymphoma Through Induction of DNA Damage and Perturbation of the DNA Damage Response.
Yuan S; Zuo W; Liu T; Fu H
Technol Cancer Res Treat; 2023; 22():15330338231208608. PubMed ID: 37880950
[No Abstract] [Full Text] [Related]
4. USP14 promotes the malignant progression and ibrutinib resistance of mantle cell lymphoma by stabilizing xpo1.
Zhang Y; Lu P; Jin S; Zhang J; Zhou Y
Int J Med Sci; 2023; 20(5):616-626. PubMed ID: 37082728
[No Abstract] [Full Text] [Related]
5. [The Latest Research Progress of Selinexor in the Treatment of Non-Hodgkin lymphoma --Review].
Tang XY; Wang Y; Xu RR
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Feb; 31(1):292-296. PubMed ID: 36765514
[TBL] [Abstract] [Full Text] [Related]
6. Nuclear Export in Non-Hodgkin lymphoma and Implications for Targeted xpo1 Inhibitors.
Trkulja KL; Manji F; Kuruvilla J; Laister RC
Biomolecules; 2023 Jan; 13(1):. PubMed ID: 36671496
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic and therapeutic significance of xpo1 in T-cell lymphoma.
Nie D; Xiao X; Chen J; Xie S; Xiao J; Yang W; Liu H; Wang J; Ma L; Du Y; Huang K; Li Y
Exp Cell Res; 2022 Jul; 416(2):113180. PubMed ID: 35489384
[TBL] [Abstract] [Full Text] [Related]
8. Effect of Prior Therapy and Disease Refractoriness on the Efficacy and Safety of Oral Selinexor in Patients with Diffuse Large B-cell lymphoma (DLBCL): A Post-hoc Analysis of the SADAL Study.
Schuster M; Zijlstra J; Casasnovas RO; Vermaat JSP; Kalakonda N; Goy A; Choquet S; Neste EVD; Hill B; Thieblemont C; Cavallo F; De la Cruz F; Kuruvilla J; Hamad N; Jaeger U; Caimi P; Gurion R; Warzocha K; Bakhshi S; Sancho JM; Follows G; Egyed M; Offner F; Vassilakopoulos T; Samal P; Ku M; Ma X; Corona K; Chamoun K; Shah J; Shacham S; Kauffman MG; Canales M; Maerevoet M
Clin Lymphoma Myeloma Leuk; 2022 Jul; 22(7):483-494. PubMed ID: 35078739
[TBL] [Abstract] [Full Text] [Related]
9. Selinexor in Combination with R-CHOP for Frontline Treatment of Non-Hodgkin lymphoma: Results of a Phase I Study.
Seymour EK; Khan HY; Li Y; Chaker M; Muqbil I; Aboukameel A; Ramchandren R; Houde C; Sterbis G; Yang J; Bhutani D; Pregja S; Reichel K; Huddlestun A; Neveux C; Corona K; Landesman Y; Shah J; Kauffman M; Shacham S; Mohammad RM; Azmi AS; Zonder JA
Clin Cancer Res; 2021 Jun; 27(12):3307-3316. PubMed ID: 33785483
[TBL] [Abstract] [Full Text] [Related]
10. Development of molecular intervention strategies for B-cell lymphoma.
Zhou W; Chen W
Expert Rev Hematol; 2021 Feb; 14(2):241-252. PubMed ID: 33263441
[TBL] [Abstract] [Full Text] [Related]
11. xpo1 expression worsens the prognosis of unfavorable DLBCL that can be effectively targeted by selinexor in the absence of mutant p53.
Deng M; Zhang M; Xu-Monette ZY; Pham LV; Tzankov A; Visco C; Fang X; Bhagat G; Zhu F; Dybkaer K; Chiu A; Tam W; Zu Y; Hsi ED; Choi WWL; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Parsons BM; van Krieken JH; Piris MA; Winter JN; Hagemeister F; Alinari L; Li Y; Andreeff M; Xu B; Young KH
J Hematol Oncol; 2020 Nov; 13(1):148. PubMed ID: 33148342
[TBL] [Abstract] [Full Text] [Related]
12. Selinexor, selective inhibitor of nuclear export: Unselective bullet for blood cancers.
Benkova K; Mihalyova J; Hajek R; Jelinek T
Blood Rev; 2021 Mar; 46():100758. PubMed ID: 32972802
[TBL] [Abstract] [Full Text] [Related]
13. Glans metastatic extra-nodal natural killer/T-cell lymphoma, nasal-type with HDAC inhibitor as maintenance therapy: a rare case report with literature review.
Fu C; Yang C; Li Q; Wang L; Zou L
Ann Palliat Med; 2020 Sep; 9(5):3602-3608. PubMed ID: 32527129
[TBL] [Abstract] [Full Text] [Related]
14. Cyclin D1-positive Mediastinal Large B-Cell lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease.
Chen BJ; Ruminy P; Roth CG; Bisig B; Mankel B; Steinhilber J; Bohers E; Jardin F; Fend F; Swerdlow SH; Copie-Bergman C; de Leval L; Quintanilla-Martinez L
Am J Surg Pathol; 2019 Jan; 43(1):110-120. PubMed ID: 30211726
[TBL] [Abstract] [Full Text] [Related]
15. Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma.
Kuruvilla J; Savona M; Baz R; Mau-Sorensen PM; Gabrail N; Garzon R; Stone R; Wang M; Savoie L; Martin P; Flinn I; Jacoby M; Unger TJ; Saint-Martin JR; Rashal T; Friedlander S; Carlson R; Kauffman M; Shacham S; Gutierrez M
Blood; 2017 Jun; 129(24):3175-3183. PubMed ID: 28468797
[TBL] [Abstract] [Full Text] [Related]
16. Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.
Sekihara K; Saitoh K; Han L; Ciurea S; Yamamoto S; Kikkawa M; Kazuno S; Taka H; Kaga N; Arai H; Miida T; Andreeff M; Konopleva M; Tabe Y
Oncotarget; 2017 May; 8(21):34552-34564. PubMed ID: 28388555
[TBL] [Abstract] [Full Text] [Related]
17. Human Exportin-1 is a Target for Combined Therapy of HIV and AIDS Related lymphoma.
Boons E; Vanstreels E; Jacquemyn M; Nogueira TC; Neggers JE; Vercruysse T; van den Oord J; Tamir S; Shacham S; Landesman Y; Snoeck R; Pannecouque C; Andrei G; Daelemans D
EBioMedicine; 2015 Sep; 2(9):1102-13. PubMed ID: 26501108
[TBL] [Abstract] [Full Text] [Related]
18. Induction of p53-mediated transcription and apoptosis by exportin-1 (xpo1) inhibition in mantle cell lymphoma.
Yoshimura M; Ishizawa J; Ruvolo V; Dilip A; Quintás-Cardama A; McDonnell TJ; Neelapu SS; Kwak LW; Shacham S; Kauffman M; Tabe Y; Yokoo M; Kimura S; Andreeff M; Kojima K
Cancer Sci; 2014 Jul; 105(7):795-801. PubMed ID: 24766216
[TBL] [Abstract] [Full Text] [Related]